Table 2.

FDA-snapshot at W48, Intention to treat- exposed (ITT-e) analysis population (n=41). Abbreviations: AE: adverse event.

	All participants	Historical resistance to lamivudine	No historical resistance to lamivudine
	(n=41)	(n=21)	(n=20)
HIV-1 RNA ≤50 copies/mL	38 (92·7)	18 (85·7)	20 (100)
Virologic failure	0 (0)	0 (0)	0 (0)
HIV-1 RNA ≥50 copies/mL	0 (0)	0 (0)	0 (0)
HIV-1 RNA ≥50 copies/mL in W48 window	0 (0)	0 (0)	0 (0)
Discontinuation Study Drug due to Lack of Efficacy	0 (0)	0 (0)	0 (0)
Discontinuation Study Drug due to other reasons and Last available HIV-1 RNA ≥50 copies/mL	0 (0)	0 (0)	0 (0)
No virologic data at W48	3 (7·3)	3 (14·3)	0 (0)
Discontinuation Study Drug Due to AE	1 (2·4)	1 (4·8)	0 (0)
Discontinuation Study Drug due to other reasons and Last available HIV-1 RNA <50 copies/mL	2 (4·9)	2 (9·5)	0 (0)